Alliqua Biomedical (NASDAQ:ALQA) shares traded 16.14% up during most recent session to reach at the closing price of $0.43. The stock exchanged hands 3.29 Million shares versus average trading capacity of 275.88 Million shares, yielding a market cap of $20.56 Million. Wall Street analysts covering the stock are projecting that the stock will reach $1.67 within the next 52-weeks. The mean target projections are based on 3 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Alliqua Biomedical (NASDAQ:ALQA) high price target of $2 and with a conservative view have low price target of $1.5.
H.C. Wainwright “Reiterates” Alliqua Biomedical (NASDAQ:ALQA) in a research note issued to investors on 4/07/17 to Buy with price target of $1.5.
Additionally on 8/10/16 H.C. Wainwright “Maintained” Alliqua Biomedical (NASDAQ:ALQA) to Buy setting price target at $2.5 and on 2/24/16 Chardan Capital “Maintained” the stock to Buy at $2.3. Furthermore on 6/26/15 Cowen & Co. “Initiates Coverage on” the stock to Outperform at $9.
On the other hand the company has Relative Strength Index (RSI 14) of 66.73 along with Average True Range (ATR 14) of 0.03, Consequently Alliqua Biomedical (NASDAQ:ALQA)’s weekly and monthly volatility is 13.39%, 9.81% respectively. The company’s beta value is at 1.72.
In terms of Buy, Sell or Hold recommendations, Alliqua Biomedical (NASDAQ:ALQA) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Alliqua Biomedical (NASDAQ:ALQA)’s minimum EPS for the current quarter is at $-0.17 and can go high up to $-0.11. The consensus mean EPS for the current quarter is at $-0.14 derived from a total of 2 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.18 earnings per share for the same quarter during last year.
Previously Alliqua Biomedical (NASDAQ:ALQA) reported $-0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.2 by $-0.03. The company posted an earnings surprise of -15%.
Alliqua Biomedical (NASDAQ:ALQA)’s revenue estimates for the current quarter are $5.07 Million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $5.1 Million in contradiction of low revenue estimates of $5.05 Million. For the current year the company’s revenue estimates are $20.77 Million compared to low analyst estimates of $20.74 Million and high estimates of $20.8 Million according to 2 number of analysts.
Currently Alliqua Biomedical (NASDAQ:ALQA)’s shares owned by insiders are 26.1%, whereas shares owned by institutional owners are 26.2%. However the six-month change in the insider ownership was recorded 71.79%, as well as three-month change in the institutional ownership was recorded 25.24%.
Alliqua Biomedical (NASDAQ:ALQA) 52-week high price stands at $1.30 and low price stands at $0.32, its price distance from 52-week high is -66.95% while its distance from 52-week low price is 34.87%. The stock hit its 52-week high on 07/26/16, and 52-week low on 06/23/17.
Alliqua Biomedical (NASDAQ:ALQA)’s trailing twelve month revenues are $18.9 Million, whereas its price to sales ratio for the same period is 1.09. Its book value per share for the most recent quarter is $0.94 while its price to book ratio for the same period is 0.46, as for as the company’s cash per share for the most recent quarter is $0.05, however its price to cash per share ratio for the same period is 8.57. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.